Myomo logo
Myomo MYO
$ 0.69 -0.33%

Annual report 2025
added 03-09-2026

report update icon

Myomo Financial Ratios 2011-2026 | MYO

Annual Financial Ratios Myomo

2025 2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-2.2 -4.9 -0.5 -4.2 -3.6 -0.5 -2.0 -1.6 - -0.0 - - - -

P/S

0.8 0.9 0.0 3.1 5.5 1.3 8.5 12.2 - 0.1 - - - -

EPS

-0.4 -0.2 -1.5 -1.9 -3.7 -20.8 -25.2 -2.9 -4.1 - - - - -

EV (Enterprise Value)

47 M 23.7 M 4.1 M 32.5 M 32.7 M 5.13 M 16.2 M 7.65 M 19.2 M 65.3 K - - - -

EBITDA per Share

-0.32 -0.16 -1.49 -1.74 -2.64 -19.3 -25.5 -45.4 - - - - - -

EV/EBITDA

-3.0 -3.0 -0.3 -1.4 -0.9 - -0.3 - - - -

PEG

- -0.04 -0.02 -0.03 0.0 - 0.0 - - - -

P/B

3.0 1.2 0.9 2.8 3.6 2.6 3.3 1.5 - -0.0 - - - -

P/CF

-2.3 -9.3 -0.6 -4.5 -4.6 -0.5 -2.1 -3.1 - -0.0 - - - -

ROE %

-136.57 -25.02 -168.59 -67.31 -99.99 -587.11 -160.55 -97.20 - 278.71 - - - -

ROA %

-40.31 -14.64 -105.50 -51.62 -78.61 -162.35 -124.57 -86.57 - -247.18 - - - -

ROCE %

-126.29 -25.11 -167.82 -66.64 -88.70 -397.58 -163.84 -52.43 - -661.69 - - - -

Current Ratio

1.4 2.4 2.7 4.3 5.0 1.6 4.2 9.3 - 1.4 - - - -

DSO

35.3 - 0.7 38.0 44.5 40.4 57.1 69.6 - 61.2 - - - -

DIO

81.8 - 76.0 78.0 99.3 174.8 128.4 145.3 - 146.4 - - - -

DPO

34.8 - 44.5 46.5 25.3 179.0 213.9 191.3 - - - - - -

Operating Cycle

117.1 - 76.7 116.0 143.8 215.2 185.5 214.9 - 207.6 - - - -

Cash Conversion Cycle

82.3 - 32.2 69.5 118.4 36.1 -28.4 23.5 - 207.6 - - - -

All numbers in USD currency

Quarterly Financial Ratios Myomo

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.09 -0.11 -0.08 - -0.03 -0.03 -0.1 - -0.06 -0.04 -0.11 - -0.4 -0.42 -0.41 - -0.36 -0.46 -0.57 - -0.7 -1.12 -2.51 - -20.79 -20.79 -20.79 - -0.21 -0.21 -0.2 - -0.21 -3.35 -1.55 - -1.09 -0.94 - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - -0.08 - - - -0.11 - - - -0.11 - -0.38 -0.42 -0.39 - -0.34 -0.46 -0.56 - -0.63 -0.95 -1.91 - -4.82 -4.67 -5.34 - -0.21 -0.21 -0.2 - -0.23 -0.83 -1.21 - -0.84 -0.67 - - - - - - - - - - - - - - - - - - - - -

ROE %

-77.72 -63.07 -48.37 -57.18 -75.59 -83.59 -83.50 -57.36 -93.54 -111.31 -127.92 -86.16 -101.81 -81.28 -72.14 -53.05 -77.06 -85.42 -94.86 -85.30 -238.10 -366.89 -479.06 -435.77 -477.01 -365.44 -265.78 -118.66 -128.77 -97.65 -116.04 -166.65 -160.84 -144.92 -81.27 10.14 10.14 4.33 - - - - - - - - - - - - - - - - - - - - -

ROA %

-37.13 -32.30 -27.25 -36.07 -47.97 -53.94 -54.64 -38.78 -62.05 -73.43 -81.46 -54.59 -66.38 -39.22 -54.03 -40.74 -59.61 -66.70 -74.25 -67.07 -109.32 -132.70 -149.23 -120.50 -152.50 -142.24 -135.12 -92.07 -101.08 -78.09 -99.16 -148.41 -209.82 -262.22 -255.22 -107.23 -107.23 -45.82 - - - - - - - - - - - - - - - - - - - - -

ROCE %

- - - - - - - - -36.04 -72.07 -100.06 -85.30 -100.74 -80.15 -70.99 -52.52 -74.52 -81.09 -86.89 -76.23 -230.92 -363.61 -487.30 -450.04 -492.19 -379.64 -273.06 -121.28 -132.81 -102.19 -75.99 -38.02 -31.36 -13.17 7.28 11.58 11.58 4.91 - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.8 1.8 2.1 2.4 2.3 2.5 2.9 2.6 2.8 3.0 3.4 2.7 2.8 - 3.5 4.3 4.0 4.5 4.3 4.7 4.7 4.7 4.7 1.4 1.4 1.4 1.4 4.5 4.5 4.5 4.5 9.1 9.1 9.1 9.1 0.2 0.2 0.2 - - - - - - - - - - - - - - - - - - - - -

DSO

55.8 55.4 39.4 - 31.0 25.5 49.4 - 37.4 24.4 45.6 - 18.3 21.0 43.1 - 34.8 27.9 33.0 - 43.8 98.3 61.1 - 63.8 44.0 44.3 - 57.3 55.2 99.0 - 55.5 88.4 86.8 - 56.7 20.6 - - - - - - - - - - - - - - - - - - - - -

DIO

97.2 95.0 92.5 - 120.7 103.7 131.4 - 81.0 79.0 118.8 - 50.8 36.8 64.9 - 56.4 77.0 109.9 - 75.4 154.1 164.2 - 121.8 105.5 110.7 - 120.8 116.6 193.1 - 147.9 186.1 164.7 - 97.6 74.9 - - - - - - - - - - - - - - - - - - - - -

DPO

51.8 63.4 51.8 - 53.9 45.7 59.6 - 56.9 45.5 59.1 - 30.1 36.3 61.4 - 50.8 67.1 65.5 - 19.3 39.3 90.3 - 124.8 108.1 139.5 - 201.2 194.3 292.0 - 194.8 245.0 334.5 - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

153.0 150.4 131.9 - 151.7 129.2 180.8 - 118.3 103.4 164.4 - 69.2 57.8 108.0 - 91.3 104.9 142.9 - 119.2 252.3 225.2 - 185.6 149.5 155.0 - 178.0 171.8 292.0 - 203.4 274.5 251.5 - 154.3 95.5 - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

101.2 87.0 80.1 - 97.8 83.5 121.1 - 61.4 57.9 105.2 - 39.0 21.5 46.6 - 40.4 37.8 77.4 - 100.0 213.0 134.9 - 60.9 41.4 15.5 - -23.1 -22.5 0.1 - 8.6 29.4 -83.0 - 154.3 95.5 - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Myomo, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 215.63 -4.38 % $ 15.2 B usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 5.78 12.23 % $ 180 M canadaCanada
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.92 2.62 % $ 167 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 9.54 - $ 735 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 3.97 3.39 % $ 111 M australiaAustralia
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.33 -1.48 % $ 21.5 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 2.55 -0.77 % $ 7.07 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 36.9 0.86 % $ 1.15 B usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.43 0.82 % $ 23.8 B britainBritain
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Electromed Electromed
ELMD
$ 24.73 0.12 % $ 209 M usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 4.21 6.31 % $ 68.7 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 26.86 -0.02 % $ 614 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.7 -7.88 % $ 16 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.67 -3.33 % $ 36.5 M usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 2.38 10.12 % $ 3.71 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 24.02 -2.02 % $ 1.63 B usaUSA
InspireMD InspireMD
NSPR
$ 1.76 -0.56 % $ 113 M israelIsrael
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 11.33 -1.31 % $ 1.53 B usaUSA
Penumbra Penumbra
PEN
$ 336.05 0.54 % $ 13.1 B usaUSA
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 2.28 -5.0 % $ 134 M israelIsrael
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.7 -5.37 % $ 138 M franceFrance
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 16.22 1.95 % $ 381 M usaUSA
Outset Medical Outset Medical
OM
$ 3.49 -1.27 % $ 53.1 K usaUSA
Inspire Medical Systems Inspire Medical Systems
INSP
$ 51.29 -1.52 % $ 1.51 B usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.29 -1.53 % $ 52.5 M usaUSA